definiens: ( ormembers of any of their ) ( as such terms are respectivelydefined in Rule 12b-2 and Rule 16a-1 of the Exchange Act ) of any suchexecutive officer, director or beneficial owner ; ( H ) any Contract involving the settlement of any Action orthreatened Action ( or series of related Actions ) ( A ) which ( x ) will involvepayments by [COMPANY] or any of its Subsidiaries after the date hereof, orinvolved such payments, in excess of $ 100 million or ( y ) will impose, orimposed, materially burdensome monitoring or reporting obligations byAllergan or any of its Subsidiaries outside the ordinary course of business ormaterial restrictions on [COMPANY] or any Subsidiary of [COMPANY] ( or, followingthe Completion, on [COMPANY] or any Subsidiary of [COMPANY] ) or ( B ) whichimpose material restrictions on the use of any material Intellectual Propertyother than, in the case of this clause ( B ), the granting of non - exclusivelicenses or sublicenses or the granting of exclusive licenses in connectionwith the settlement of ANDA - related litigation in the ordinary course ofbusiness ; ( I ) any stockholders, investors rights, registration rights or similaragreements or arrangements with respect to the Equity Securities ofAllergan or any of its Subsidiaries ; and ( J ) any other Contract required to be filed by [COMPANY] pursuant toItem 601(b)(10 ) of Regulation S - K